C-PET Current Field Trial Data

C-PET Evaluations To study the effectiveness of C-PET, we have embarked on two parallel approaches.  The first is a series of controlled clinical studies in partnership with world class academic institutions, and the second is a large-scale, uncontrolled field trial to assess the effectiveness of C-PET in a real world setting. Our controlled studies are currently underway and when data become available they will be presented as abstracts or presentations at key industry meetings.  Our field trials are also ongoing, and we have provided an interim assessment below.  For the latest information, be sure to check back for periodic updates. C-PET Field Trial Interim Results The C-PET field trial is meant to provide a broad, multi-center (38 evaluation sites), assessment of C-PET efficacy in treating osteoarthritis, and a variety of tendon and ligament conditions.  Because osteoarthritis is not a self-limiting disease, the lack of a control does not detract from the value of the data presented,

where it may be more important in animals treated for acute tendon and ligament injuries.  Regardless of the limitation of such evaluations, the data shows that benefits do accrue and justify further investigation in the controlled trials now underway. 

Dogs enrolled in the C-PET field tests were evaluated before and 3 months after C-PET treatment using the Hudson Visual Analog Scale (VAS) questionnaire¹, an assessment tool correlated with force plate kinetics.  As of this writing, data from 44 dogs are available, with an additional 110 dogs treated and awaiting their 3 month follow-up. 

Overall, our interim data are very encouraging.  Dogs treated with C-PET showed significant improvements in VAS scores.  This is particularly impressive in the osteoarthritis treatment group, since these dogs are not likely to improve in the absences of an intervening therapy.  Interestingly, there appears to be an age-dependent response to C-PET in the osteoarthritis group with dogs younger than 10 demonstrating greater improvement than older dogs.  We will continue to monitor this trend as data collection continues.  

¹Hudson et al. Assessing repeatability and validity of a visual analogue scale questionnaire for use in assessing pain and lameness in dogs. Am J Vet Res. 2004 Dec;65(12):1634-43.

Subset analysis of C-PET treatment by indication

Box plots (median, 25th, 75th quartiles, and range) of 11-question average of Hudson Visual Analog Scale (VAS) results measured before and 3 months after a single C-PET treatment. P-values reported are for Wilcoxon matched-pairs signed rank test, a standard method of analyzing nonparametric paired data. Overall patients showed significant improvements after treatment with C-PET (A). Segmented by indication, both the patient group treated for osteoarthritis (B) and the patient group treated for tendon or ligament injuries (C) showed significant improvements. When further segmented by age, dogs treated either indication dogs that were younger than 10 years of age showed significant improvement (D and F) while older dogs improved, but not to the same extent (E and G). This may be because of the small sample size among older dogs.